[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:metastatic-malignant-neoplasm-in-the-brain":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":317},"Metastatic Malignant Neoplasm in the Brain",71,60,[8,16,23,30,36,42,48,54,61,67,73,79,85,90,97,103,109,114,120,127,133,139,145,151,157,163,169,175,181,187,193,199,205,211,217,223,229,235,241,247,253,258,264,270,276,282,288,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02390518","Stereotactic Radiosurgery Dose Escalation for Brain Metastases",[12],"Phase 1","RECRUITING","2026-08-26T02:18:13.438956Z","2026-07-05T05:32:16.769973Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03449238","Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.730452Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05419076","A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain",[27],"Phase 2","2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.712863Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT04965064","Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling",[27],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.668617Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05048212","A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",[27],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:29.384523Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT01891318","Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I\u002FII Study",[20],"2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.369053Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT02747303","Frameless Stereotactic Radiosurgery for Intact Brain Metastases",[27],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.055505Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06328686","Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases",[58],"Early Phase 1","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:29.027386Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06857006","Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases",[],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:28.959733Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07227610","Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)",[27],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:28.821716Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07268053","A Phase 0\u002F1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases",[58],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:28.794018Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05124912","REMASTer: REcurrent Brain Metastases After SRS Trial",[],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.728440Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":59,"content_modified":89},"NCT04343157","UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases",[27],"2026-05-05T02:43:28.656967Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":95,"content_modified":96},"NCT03750227","Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors",[94],"Phase 3","2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.532569Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05673928","A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)",[27],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:28.183681Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT03184038","Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery",[],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.976762Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":52,"content_modified":113},"NCT05045950","Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique",[27],"2026-05-05T02:43:27.966442Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05013892","NTS-WBRT in Brain Metastases",[27],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.956518Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":125,"content_modified":126},"NCT06072807","Brain [18F]-FES PET\u002FCT in Patients With Estrogen-Receptor Positive Breast Cancer",[124],"Phase 4","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.955071Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT03726359","Phase I Study of Fractionated Stereotactic Radiation Therapy",[12],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.732087Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT03550391","Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases",[94],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:27.517989Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT03741673","Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases",[94],"2026-08-03T03:45:36.723745Z","2026-05-05T02:43:27.447938Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07053033","Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)",[27],"2026-08-26T02:14:59.425132Z","2026-05-05T02:43:27.130562Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05317858","Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets",[94],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:27.060350Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07132190","Stereotactic Radiation for Growing\u002FChanging Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction",[27],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:26.977886Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06764940","A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases",[27],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:26.756648Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06194929","Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",[20],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.716817Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT04923542","Stereotactic Radiation & Abemaciclib in the Management of HR+\u002FHER2- Breast Cancer Brain Metastases",[20],"2026-08-26T02:15:29.632183Z","2026-05-05T02:35:31.928134Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06649058","EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active",[27],"2026-08-26T02:17:28.381459Z","2026-05-05T02:35:31.876177Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05386108","Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+\u002FHER-2- Breast Cancer",[20],"2026-08-26T02:16:46.147215Z","2026-05-05T02:35:31.632277Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05222620","SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial",[27],"2026-08-26T02:18:48.678868Z","2026-04-29T02:57:57.165169Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT05987644","Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements",[20],"2026-08-26T02:16:40.941792Z","2026-04-29T02:57:57.103134Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[27],"2026-08-26T02:15:14.574786Z","2026-07-05T05:32:16.794666Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT06136884","A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:29.054284Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT07139990","Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:26.849521Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06132685","Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial",[27],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:26.663660Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT04689048","Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery",[12],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:27.175882Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT05554302","Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis",[27],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.338869Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT05376878","An Investigational Scan (64Cu-DOTA-Trastuzumab PET\u002FMRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis",[124],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.325102Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT06159335","18F-FLUC PET\u002FMR in Patients With Brain Mets",[94],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.220079Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":155,"content_modified":257},"NCT04033497","Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases",[],"2026-05-05T02:43:28.188601Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT05452005","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer",[12],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:27.846282Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT06055790","Feasibility of 18F-Fluciclovine PET\u002FCT to Identify Brain Metastasis",[27],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:27.800682Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT06048094","18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery",[12],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.097145Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT07339085","Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis",[],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.058160Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT05996432","Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy",[58],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:26.710686Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT06650163","Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors",[12],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.572146Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT05139277","Evaluation of the CONVIVO System",[],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:29.047316Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT06101069","Development of MRF for Characterization of Brain Tumors After Radiotherapy",[],"2026-08-26T02:16:12.203827Z","2026-05-05T02:35:31.765025Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":310,"content_modified":311},"NCT07462507","Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1",[27],"2026-08-26T02:16:38.053590Z","2026-05-05T02:35:31.695581Z",[313],{"biomarker":314,"count":315,"slug":316},"ERBB2 Gene",5,"erbb2-gene",[318,322,326,330,333,337,341,344,348,351,354,358,361,364,367,370,374,377,380,383,387,390,393,396],{"state":319,"count":320,"slug":321},"Florida",14,"florida",{"state":323,"count":324,"slug":325},"California",13,"california",{"state":327,"count":328,"slug":329},"New York",12,"new-york",{"state":331,"count":328,"slug":332},"Texas","texas",{"state":334,"count":335,"slug":336},"Ohio",9,"ohio",{"state":338,"count":339,"slug":340},"Massachusetts",8,"massachusetts",{"state":342,"count":339,"slug":343},"North Carolina","north-carolina",{"state":345,"count":346,"slug":347},"Arizona",7,"arizona",{"state":349,"count":346,"slug":350},"Illinois","illinois",{"state":352,"count":346,"slug":353},"Maryland","maryland",{"state":355,"count":356,"slug":357},"Wisconsin",6,"wisconsin",{"state":359,"count":315,"slug":360},"Georgia","georgia",{"state":362,"count":315,"slug":363},"Michigan","michigan",{"state":365,"count":315,"slug":366},"New Jersey","new-jersey",{"state":368,"count":315,"slug":369},"Virginia","virginia",{"state":371,"count":372,"slug":373},"Indiana",4,"indiana",{"state":375,"count":372,"slug":376},"Minnesota","minnesota",{"state":378,"count":372,"slug":379},"Missouri","missouri",{"state":381,"count":372,"slug":382},"South Carolina","south-carolina",{"state":384,"count":385,"slug":386},"Alabama",3,"alabama",{"state":388,"count":385,"slug":389},"Colorado","colorado",{"state":391,"count":385,"slug":392},"Iowa","iowa",{"state":394,"count":385,"slug":395},"Oklahoma","oklahoma",{"state":397,"count":385,"slug":398},"Oregon","oregon"]